{"id":"W2762161610","doi":"10.1093/annonc/mdx377.003","title":"KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dabrafenib; Medicine; Trametinib; Pembrolizumab; Neutropenia; Discontinuation; Regimen; Melanoma; Internal medicine; Oncology; Metastatic melanoma; Vemurafenib; Gastroenterology; Cancer research; Cancer; Chemotherapy; Immunotherapy; MAPK/ERK pathway","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003042955,0.001112049,0.002165472,0.0006623306,0.0003855086,0.00179248,0.002035999,0.002115018,0.01047959],"category_scores_gemma":[0.002141976,0.0006173286,0.001809065,0.0006628737,0.0002698627,0.001110748,0.0005589081,0.003307812,0.003583902],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00157663,"about_ca_system_score_gemma":0.00165976,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002314773,"about_ca_topic_score_gemma":0.01233794,"domain_scores_codex":[0.999498,0.0001698216,0.00004256994,0.00006100282,0.0001459553,0.00008264141],"domain_scores_gemma":[0.9986312,0.000291748,0.0002493816,0.00007273244,0.0003118483,0.0004430331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.06115576,0.005254654,0.004211243,0.005438595,0.003047779,0.0006153166,0.0001770033,0.002404536,0.02620783,0.001119137,0.341754,0.5486141],"study_design_scores_gemma":[0.1845784,0.06318021,0.03368302,0.001702741,0.007609376,0.002044003,0.0001215518,0.002542876,0.008755711,0.001713717,0.6939149,0.0001535292],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.3200725,0.2862216,0.01193955,0.05951978,0.01732207,0.01486103,0.133965,0.003545668,0.1525528],"genre_scores_gemma":[0.4169831,0.1839094,0.02832472,0.09153223,0.008027614,0.009524914,0.1557115,0.001194191,0.1047923],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01047959,"threshold_uncertainty_score":0.03505772,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06839828692160825,"score_gpt":0.3901515468075271,"score_spread":0.3217532598859188,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}